Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study

Conclusion: Bone-directed therapy (Zoledronic acid) leads to both subjective and objective improvement in bone health of prostate cancer patients on ADT.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research